Quick read
Researchers are exploring the potential of combining Shingrix and a GLP-1 agonist to preserve beta cells in individuals with recent-onset Type 1 Diabetes.
What's happening
A Phase 2-3 clinical trial, SHIELD-T1D, is investigating the combination of Shingrix and a GLP-1 agonist to preserve beta cells in individuals with recent-onset Type 1 Diabetes.
Why this matters to you
ā¢This trial could provide valuable insights into the role of GLP-1 agonists in preserving beta cells in T1D patients.
ā¢The combination of Shingrix and a GLP-1 agonist may offer a novel therapeutic approach for Type 1 Diabetes management.
ā¢The results of this trial could have significant implications for the development of new treatments for T1D.
Let's talk about it
What potential benefits or drawbacks do you see in combining Shingrix and a GLP-1 agonist for beta-cell preservation in T1D patients?